Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05025865 · ClinicalTrials.gov registry record · Early Phase 1
HA35 Acute Alcohol Study
A Early Phase 1 study of Healthy (Controls), sponsored by The Cleveland Clinic.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT05025865: Recruiting Early Phase 1 study of Healthy (Controls), sponsored by The Cleveland Clinic.
NCT05025865 is a Early Phase 1 study of Healthy (Controls) that is actively recruiting participants, run by The Cleveland Clinic. The registered enrollment target is 24 participants, below the 120-participant average among 16 other Healthy (Controls) trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05025865, a Early Phase 1 study of Healthy (Controls), is actively recruiting participants, sponsored by The Cleveland Clinic.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
Eligible subjects will be asked to take a placebo/treatment capsule for a total of 3 days and then participate in a study visit on the fourth day. This study visit will include a medical exam, clinical labs, questionnaires, body composition measurements, and urine and stool collections. Additionally, participants will consume a sugar cocktail to measure their gut permeability, participate in an acute ethanol challenge, and undergo two muscle biopsies. The study will take approximately 3-4 hours and a designated driver will need to drive the participant home. On the fifth day, you will be asked to return to drop of the 24-hour urine collection.
Primary Outcome
change in units/liter (U/L)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Sodium Hyaluronate
Study Locations (1)
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2022-02-01 |
| Est. Completion | 2027-10-01 |
| Phase | Early Phase 1 |
What NCT05025865 shows while recruiting
NCT05025865 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 120-participant average among 16 other Healthy (Controls) trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Healthy (Controls) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05025865 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05025865 about?
NCT05025865 is a clinical study titled "HA35 Acute Alcohol Study". Eligible subjects will be asked to take a placebo/treatment capsule for a total of 3 days and then participate in a study visit on the fourth day. This study visit will include a medical exam, clinical labs, questionnaires, body composition measurements, and urine and stool collections. Additionally...
What is the current status of trial NCT05025865?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2022-02-01. Estimated completion is 2027-10-01.
What conditions does trial NCT05025865 study?
This clinical trial studies the following conditions: Healthy (Controls).
What interventions are being tested in trial NCT05025865?
The interventions under investigation include: Placebo (DRUG), Sodium Hyaluronate (DRUG).
Who is sponsoring clinical trial NCT05025865?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05025865 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy (Controls)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05025865's enrollment target sits among peer trials
24 16th of 16 higher than 1 of 16 other Healthy (Controls) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy (Controls) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PET Imaging Evaluation of [11C]SY08
RECRUITING · Early Phase 1
-
Cold and Heat Investigation to Lower Levels of Depression
RECRUITING · NA
-
Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake
RECRUITING · Phase 2
-
Decoding Emotional Dynamics in Bipolar Disorder
RECRUITING · NA
-
Subthreshold Vestibular Stimulation as a Strategy for Rehabilitation
RECRUITING · NA
-
A Repository to Study Host-Microbiome Interactions in Health and Disease
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI